A liquid biopsy to detect circulating tumor DNA after surgery for stage 2 colon cancer reduces the use of chemotherapy without sacrificing recurrence-free survival.
Further research is needed, though, to overcome barriers to the routine clinical use of liquid biopsy for patients with hepatocellular carcinoma (HCC).
CZ Biohub Network president Stephen Quake reveals that they are looking to expand across the United States. Apply to become the next Biohub at czbiohub.org.